Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Repaglinide (1mg) + Metformin (500mg) Tablet
Therapeutic Category
Antidiabetic, Cardiology, Diabetic
Dosage Form
Tablet
Packaging Type
Blister
Packaging
10*10
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Repohike M Tablet containing Repaglinide and Metformin is used for the management of type 2 diabetes mellitus. It helps improve glycemic control and supports effective blood glucose management as part of a comprehensive diabetes care plan.
Repaglinide works by stimulating insulin release from the pancreas, helping control post-meal blood sugar levels, while Metformin helps reduce hepatic glucose production and improves insulin sensitivity, contributing to overall glycemic control.
The tablet is widely prescribed in diabetology and general medicine practice for patients requiring combination therapy to achieve better blood sugar management, leading to consistent prescription demand.
With the increasing prevalence of diabetes and growing demand for effective anti-diabetic therapies, this product offers strong business potential for retailers and distributors. Its combination formulation, established clinical efficacy, and steady market demand make it a reliable product for growth in the anti-diabetic segment.
Some patients may experience hypoglycemia, nausea, vomiting, diarrhea, abdominal discomfort, headache, dizziness, weakness, or loss of appetite. Rarely, severe hypoglycemia, liver function abnormalities, allergic reactions, or lactic acidosis associated with Metformin may occur and require immediate medical attention.
Repohike M Tablet is indicated for the management of Type 2 Diabetes Mellitus in adults when diet, exercise, and single-drug therapy do not provide adequate glycemic control. It helps reduce fasting and post-meal blood glucose levels and supports long-term diabetes management.
This medicine should be used strictly under medical supervision. Regular monitoring of blood glucose levels, kidney function, and liver function is recommended during treatment. Patients should maintain a balanced diet, regular exercise routine, and adhere to prescribed meal schedules to reduce the risk of hypoglycemia. Use cautiously in patients with kidney disease, liver impairment, or conditions predisposing to lactic acidosis.
Store in a cool, dry place below 25°C, protected from moisture and direct sunlight. Keep the tablets in their original packaging and out of reach of children.
Composition : Dapagliflozin (10mg) + Metformin (500mg) ER + Sitagliptin (100mg) Tablet
Composition : Dapagliflozin 10mg + Metformin Hydrochloride I.P. 1000mg Tablets
Composition : Dapagliflozin 10mg + Metformin Hydrochloride I.P. 500mg Tablets
Composition : Dapagliflozin 10mg Tablets
Composition : Dapagliflozin 5mg Tablets
Composition : Dapagliflozin Propanediol Monohydrate 10mg + Vildagliptin I.P. 100mg Tablets
Composition : Sitagliptin Phosphate I.P. 100mg + Dapagliflozin Propanediol U.S.P. 10mg Tablets
Composition : Aspirin 75mg + Rosuvastatin 10mg + Clopidogrel 75mg Tablet
Composition : Aspirin 75mg + Rosuvastatin 20mg + Clopidogrel 150mg Tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.